COMP <GO>
KYMR vs QGEN // 10Y YIELD & FRED MACRO BETA
Kymera Therapeutics Inc. (NASDAQ) VS. Qiagen N.V. (NYSE) • 15-METRIC TALLY: KYMR 3
— QGEN 8
■ METRIC PARITY
LAST: $126.63 (+3.29%) • MKT CAP: $10.81B
macro-sensitivity
0.95
LAST: $50.22 (-0.24%) • MKT CAP: $10.35B
macro-sensitivity
0.95
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KYMR VS. QGEN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KYMR | QGEN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 62.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -21.40% | 8.00% | -29.40 | QGEN | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 17.6x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.30% | 4.37% | -6.67 | QGEN | /fcf-yield <GO> |
| Operating Margin | -60.00% | 22.30% | -82.30 | QGEN | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 20.30% | +47.70 | KYMR | /net-margins <GO> |
| Revenue Growth (YoY) | -16.70% | 5.70% | -22.40 | QGEN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.52% | -0.52 | QGEN | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 3.54 | +22.46 | KYMR | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 9/9 | -5.00 | QGEN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 66.0 | 71.0 | -5.00 | QGEN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 0.95 | 0.95 | 0.00 | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 30.4x | 22.7x | +7.70 | QGEN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.81B | $10.35B | $461.5M | KYMR | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KYMR REV | QGEN REV | KYMR GROSS % | QGEN GROSS % | KYMR FCF | QGEN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $39.2M | $2.09B | 0.0% | 62.2% | -$234.3M | $453.3M |
| FY 2024 | $47.1M | $1.98B | 0.0% | 48.9% | -$207.3M | $506.4M |
| FY 2023 | $78.6M | $1.97B | — | — | -$106.4M | $371.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KYMR // BETA 0.95
QGEN // BETA 0.95